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Telemedicine and telehealth services (defined as patient interactions facilitated via video-conferencing software) are becoming a popular technology for medical practice. Before the start of the coronavirus disease 2019 (COVID-19) pandemic, multiple medical specialties were increasingly beginning to integrate telemedicine services into their clinical workflows. Radiation oncology departments have previously incorporated video-conferencing technology into multiple components of a patient\'s care (multidisciplinary tumor boards, educational conferences, and even radiation therapy treatment planning),[@bib1] but there have only been a handful of reports in other countries on the use of telemedicine to follow patients with cancer in rural or underserved areas.[@bib1], [@bib2], [@bib3] There have been no reports on the use of telemedicine services specifically for radiation oncology, but a pilot study was funded by the Radiation Oncology Institute in 2018 to assess the utility of telemedicine as part of a survivorship program.[@bib4]

With the development of the COVID-19 pandemic, health care practices and radiation oncology departments began to incorporate telemedicine services to practice social distancing and minimize the chances of disease spread. Given the severity of this pandemic, it will likely fundamentally affect the use of these services for years to come. Because our institution and radiation oncology department have used telemedicine services for many years (with hundreds of patients seen), we would like to report on our departmental experience to guide other radiation oncology practices on its long-term use for clinical evaluation and patient care.

Experience {#sec2}
==========

Our institution, the University of Texas Medical Branch (UTMB), has an established telemedicine program that provides clinical services for a number of remote locations, including rural communities,[@bib5] polar research stations,[@bib6] and the Texas Department of Criminal Justice (TDCJ) state prison system.[@bib7] It represents the largest telehealth network in the world, with over 300 sites and 60,000 patient encounters a year.[@bib5] The large majority of patient volume for our institution is via the TDCJ system. Before the COVID-19 pandemic, the TDCJ system was the only source of telemedicine patients for the radiation oncology department, which is the focus of this article. UTMB has an agreement with the TDCJ where a large portion of inmates in the system receive specialty medical care via UTMB. Inmates have unit providers (physicians and midlevel providers) at their prison units who can manage chronic health problems (including primary care, human immunodeficiency virus, dialysis, mental health, and wound care) but anything requiring further specialty care (such as radiation oncology) is managed by UTMB.

When an inmate is referred to radiation oncology, they receive standard-of-care workup (physical examination, laboratory testing, and imaging) and treatment (including intensity modulated radiation therapy, stereotactic body radiation therapy, stereotactic radiosurgery, and brachytherapy) as appropriate, just like any other patient. After therapy is completed, patients may be seen for follow-up in person or via telemedicine. This decision is made by the treating physician only and typically depends on the disease site being treated. For example, patients with prostate cancer are seen in person for the first follow-up visit, and after that they are seen via telemedicine with remote monitoring of prostate-specific antigen levels. In contrast, for patients with head and neck cancer, follow-up appointments are seen in person for the first several visits to monitor for disease recurrence and recovery from acute side effects. After that, they are typically seen via telemedicine. The majority of patients seen via telemedicine are patients with prostate cancer, which is largely due to disease prevalence. Most telemedicine encounter visits involve patients within the first 2 years of radiation treatment completion.

Telemedicine software and equipment (Tandberg 990 Codecs; Polycom, CA) is present at the prison unit and UTMB. This typically consists of webcams, liquid crystal display monitors, and speakers. Dedicated telemedicine coordinators are present at UTMB to help facilitate appointment scheduling and logistics with communications/connections. Nurses are present at the prison unit to collect vital signs and relay recommendations from the treating physicians to the prison's unit providers. UTMB providers also have access to the prison's electronic health record to view clinical information.

During the telemedicine visit, radiation oncologists may assess inmates for signs/symptoms of cancer recurrence, treatment side effects, or long-term toxicities. If there are any clinical concerns (with a low threshold of suspicion), in-person appointments with their radiation oncologists can be scheduled quickly. If there are no concerning/alarm symptoms, the inmates will continue to be followed in-person by their unit providers (where basic labs and imaging can be ordered as needed) and their radiation oncologists via telemedicine appointments. If imaging studies are required, they are completed either locally (close to their unit) or at our institution before their next scheduled appointment; the imaging reports are routed to the ordering physician for review and further recommendations. In between telemedicine appointments, if there is any concerning change in the clinical course of an inmate (abnormal symptoms, labs, or imaging findings), the treating radiation oncologist is notified and an in-person appointment is scheduled quickly.

In our department, approximately 250 radiation oncology patient encounters occur via telemedicine each calendar year and the program has been in place for our department since 2008. Inmates in the TDCJ express great appreciation for this opportunity, as a journey to UTMB may involve several days of arduous travel back and forth. Owing to their protected research status, collecting prospective data from inmates is restricted, but previously reported internal data indicate high degrees of satisfaction for patients, nurses, and specialty physicians.[@bib7] The telemedicine system has also served as a way to limit costs in an increasingly expensive health care environment; based on the most recent reported data from 2015, Texas spent \$4077 per inmate, which is less than the median state expenditure of \$5720 and \$15,000 less than the state with the highest expenditure, California, at \$19,796.[@bib8]

Discussion {#sec3}
==========

Given the rapidly growing concerns for disease spread and virulence of COVID-19, telemedicine services have been incorporated emergently into radiation oncology practices as a means to practice social distancing and minimize disease transmission. It is unclear how long these precautionary measures will need to remain in place. We aim to share our long-term experience to help guide its use in other radiation oncology practices for extended durations.

Based on our institutional experience, there are several benefits to incorporating telemedicine services into a routine radiation oncology clinical workflow. First, incorporating telemedicine services may serve as a way to improve efficiency by reducing the time and costs needed for follow-up appointments. In addition, telemedicine also allows for increased convenience for patients, particularly for those from rural/underserved areas who may have to travel long distances for care and evaluation. Telemedicine also allows for continuity of care with patients who would otherwise not be able to follow up with their treating radiation oncologists. The treating physician is the person who is going to be most familiar with a patient's chances for disease control, side effects, complications, and long-term toxicities. Leaving survivorship follow-up to other health care providers may lead to suboptimal clinical management.

There are also potential downsides to incorporating telemedicine services. Telemedicine may further mitigate the role of physical examination, which is an important tool for assessing disease recurrence (ie, digital rectal examinations for prostate cancer, flexible laryngoscopies for head and neck cancer, pelvic examinations for gynecologic cancers, etc). However, this downside could be minimized by using telemedicine for follow-up after 3 to 5 years posttreatment, when the risk of recurrence is lower. In addition, telemedicine need not be solely used as a way to *replace* in-person follow-up visits, but as a supplementary tool to *screen* patients who need in-person follow-up visits. In addition, further improvements in technology may even allow for remote/virtual physical examinations.

Future Directions {#sec4}
=================

Regardless of the current merits of incorporating telemedicine into clinical care, this technology is already being implemented across the health care system as a means of evaluating patients while minimizing the risk of COVID-19 transmission in the setting of a pandemic. Based on our institutional experience, our long-term vision for telemedicine is as an excellent (and cost-efficient) tool to provide long-term follow-up for patients, especially for those who live far away in rural or underserved areas. This would also allow for increased compliance with survivorship programs and better data collection of long-term toxicity and recurrence rates.

With the increased consolidation of health care systems, one can even envision it as a system for patients who require specialized radiation therapy (proton therapy, brachytherapy, stereotactic radiosurgery/stereotactic body radiation therapy, etc) in major cities/centers. They can travel to a nearby satellite facility for follow-up, where they can not only undergo imaging, laboratory testing, and in-person examinations as needed but also be seen by their treating radiation oncologist via telemedicine. We believe our institutional experience serves as a good model, and we look forward to the reports on its use during the COVID-19 pandemic as well as its use in the pilot study funded by the Radiation Oncology Institute.
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